Decoding genetic interactions to advance cancer care

A BETTER FUTURE FOR CANCER PATIENTS

1,851,238 new cancer cases every year*

80% patients treated in community settings**

50% cases not undergoing genetic testing despite recommendations**

* 2022 CDC
** Wang et al. JAMA Oncology. 2025

Current clinical sequencing analysis is

SIMPLISTIC AND HASN’T CHANGED

in the last decade

We have developed a scalable genetic interaction map – the Tumour Interactome Atlas™ – that analyses cancer cells genetic interactions to inform better diagnosis and treatment.

Our GOAL

We aim to translate the insights generated by the Tumour Interactome Atlas™ into an easy-to-use application that will enable physicians to provide more precise diagnosis, and identify more effective treatment for brain cancer and beyond.

Intervance is an early-stage start-up positioned at the cutting edge of healthcare technology. Leveraging advancements in clinical genetic expression data and machine learning, our aim is to revolutionize the approach to cancer treatment. Our innovative solutions empower physicians with data-driven insights, enabling them to make more informed decisions and ultimately provide improved care for their patients. Our mission is to transform the landscape of oncology, ensuring a better future for cancer patients through the power of precision medicine.